Theralase Technologies Inc. V.TLT

Going concern

[jmm1228]

Seems to me that the transition from an R&D mission to a going concern is a primary investor worry. 

It worries me. There is a dearth of going concern executive talent here and no signals that this huge breakthrough can be skillfully advanced to market with the current skill set. 

 Until this fear is quelled and TLT trading moves to abmore stable exchange,the slog upwards will be tough.

The two PP'sare absolutely essential at this point whatever direction  this takes.

Having a position in what is almost surely a major historical medical feat is getting haltingly more secure and in 60 days will reach another threshold. 

The science looks to be very sound, the transition to a going concern is questionable. If the market is telling us something it this, IMO.

I am hoping that this superb technology ends up in the stable of a Big Pharma giant and soon.

What else makes sense?

[langosta]

Feb 15/2019 Shawn Shirazi appointed CEO of Drug Division. Aug 20/2021 Shawn Shirazi resigns.                                              Length of stay    approx. 2,5yrs Feb 15/2019 Kipton Lade appointed CEO of Device Division. Nov 1/2019   Kipton Lade resigns

[CAinPlap]

My opinion is they all saw that were not in long term plans so moved on. Except Dr Vera. That one still puzzles me.

[DJDawg]

It is odd and speaks to the problems with the company. I've heard that it is not a fun place to work. The science and the results of that science is all that give me faith. TLT management....not as much.

[Infinity]

Langosta,  you have raised a valid point that has been in the minds of pretty much every investor who are risking their hard earned money, believing in the Scope and immense potential for PDT to treat multiple forms of a dreaded disease.   The turnover of Management is certainly NOT  normal, especially for a company that employs less than 25 people!!    I guess

[2b7f6fab]

None of the below listed ceo's would have ever been needed if RW had not been removed as ceo. Regarding Dr Vera, I never understood all the hoopla on this board when she was hired.  An administrative person like her can only contribute so much.  The trial results will speak for themselves.

[CancerSlayer]

  Yep...The value in any emerging biotech is generally in its potential.  Re: acquisition value, TLT has some unique advantages.   Firstly, they have managed to successfully conduct a clinical trial thus far & not create a deficit of "hundreds of millions"...unlike other trials.  Although financial hiccups are to be expected in drug development, especially for